Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Sustained 24-hour efficacy of once-daily indacaterol in patients with copd

LaForce Craig, Janssens Eduard,de Teresa Parreño Luis,Iqbal Amir,Young David,Owen Roger,Higgins Mark,Kramer Benjamin

Chest（2009）

Cited 1|Views4
No score
Abstract
PURPOSE: Indacaterol is a novel, once-daily (qd), inhaled long-acting β2-agonist. This study characterized the 24-h lung function profile of indacaterol compared to placebo and open-label salmeterol in patients with COPD. The primary objective was to assess the superiority of indacaterol (300μg qd) over placebo in terms of 24-h post-dose (trough) FEV1 (mean of 23h 10min and 23h 45min post-dose values) after 14 days of treatment.
More
Translated text
Key words
copd,once-daily
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined